Predicting response to treatment in gastroesophageal junction adenocarcinomas

combining clinical, imaging, and molecular biomarkers

Gillian H. Bain, Russell D. Petty (Lead / Corresponding author)

    Research output: Contribution to journalArticle

    19 Citations (Scopus)

    Abstract

    The incidence of adenocarcinomas of the gastroesophageal junction (GEJ) is rapidly rising, and even in early-stage locoregional confined disease the 5-year survival rate rarely exceeds 25%-35%. Randomized trials and meta-analyses have demonstrated a benefit with neoadjuvant or perioperative chemotherapy and with neoadjuvant chemoradiotherapy. However, the optimal approach in individual patients is not clear and remains controversial. A consistent finding is that patients who have a histopathological response to neoadjuvant therapy are more likely to receive a survival benefit. These clinical data provide a strong argument for the urgent development of methods to predict histopathological response to neoadjuvant therapies for GEJ adenocarcinoma. Published data demonstrate that clinicopathological features (tumor location), imaging (fluorodeoxyglucose-positron emission tomography "metabolic response"), and tissue/molecular biomarkers may all have a predictive value for neoadjuvant therapies. However, it is uncertain from published data whether or not they will be useful for clinical decision making in individual patients. Existing candidate biomarkers need to be properly qualified and validated and novel biomarkers are required; and an optimal approach should involve the combination and integration of clinical, imaging, and molecular biomarkers. This review presents the evidence base and discusses novel experimental approaches for the combination of biomarker modalities to allow optimization of an individualized treatment approach in GEJ adenocarcinoma patients that may be relevant to other tumor types as well.

    Original languageEnglish
    Pages (from-to)270-284
    Number of pages15
    JournalOncologist
    Volume15
    Issue number3
    DOIs
    Publication statusPublished - Mar 2010

    Fingerprint

    Esophagogastric Junction
    Molecular Imaging
    Adenocarcinoma
    Biomarkers
    Neoadjuvant Therapy
    Therapeutics
    Chemoradiotherapy
    Positron-Emission Tomography
    Meta-Analysis
    Neoplasms
    Survival Rate
    Drug Therapy
    Survival
    Incidence

    Keywords

    • Adenocarcinoma
    • Diagnostic Imaging
    • Esophageal Neoplasms
    • Esophagogastric Junction
    • Humans
    • Prognosis
    • Stomach Neoplasms
    • Treatment Outcome
    • Tumor Markers, Biological

    Cite this

    @article{5411e9f6bf2547f9a575e374d64766d3,
    title = "Predicting response to treatment in gastroesophageal junction adenocarcinomas: combining clinical, imaging, and molecular biomarkers",
    abstract = "The incidence of adenocarcinomas of the gastroesophageal junction (GEJ) is rapidly rising, and even in early-stage locoregional confined disease the 5-year survival rate rarely exceeds 25{\%}-35{\%}. Randomized trials and meta-analyses have demonstrated a benefit with neoadjuvant or perioperative chemotherapy and with neoadjuvant chemoradiotherapy. However, the optimal approach in individual patients is not clear and remains controversial. A consistent finding is that patients who have a histopathological response to neoadjuvant therapy are more likely to receive a survival benefit. These clinical data provide a strong argument for the urgent development of methods to predict histopathological response to neoadjuvant therapies for GEJ adenocarcinoma. Published data demonstrate that clinicopathological features (tumor location), imaging (fluorodeoxyglucose-positron emission tomography {"}metabolic response{"}), and tissue/molecular biomarkers may all have a predictive value for neoadjuvant therapies. However, it is uncertain from published data whether or not they will be useful for clinical decision making in individual patients. Existing candidate biomarkers need to be properly qualified and validated and novel biomarkers are required; and an optimal approach should involve the combination and integration of clinical, imaging, and molecular biomarkers. This review presents the evidence base and discusses novel experimental approaches for the combination of biomarker modalities to allow optimization of an individualized treatment approach in GEJ adenocarcinoma patients that may be relevant to other tumor types as well.",
    keywords = "Adenocarcinoma, Diagnostic Imaging, Esophageal Neoplasms, Esophagogastric Junction, Humans, Prognosis, Stomach Neoplasms, Treatment Outcome, Tumor Markers, Biological",
    author = "Bain, {Gillian H.} and Petty, {Russell D.}",
    year = "2010",
    month = "3",
    doi = "10.1634/theoncologist.2009-0293",
    language = "English",
    volume = "15",
    pages = "270--284",
    journal = "Oncologist",
    issn = "1083-7159",
    publisher = "AlphaMed Press",
    number = "3",

    }

    TY - JOUR

    T1 - Predicting response to treatment in gastroesophageal junction adenocarcinomas

    T2 - combining clinical, imaging, and molecular biomarkers

    AU - Bain, Gillian H.

    AU - Petty, Russell D.

    PY - 2010/3

    Y1 - 2010/3

    N2 - The incidence of adenocarcinomas of the gastroesophageal junction (GEJ) is rapidly rising, and even in early-stage locoregional confined disease the 5-year survival rate rarely exceeds 25%-35%. Randomized trials and meta-analyses have demonstrated a benefit with neoadjuvant or perioperative chemotherapy and with neoadjuvant chemoradiotherapy. However, the optimal approach in individual patients is not clear and remains controversial. A consistent finding is that patients who have a histopathological response to neoadjuvant therapy are more likely to receive a survival benefit. These clinical data provide a strong argument for the urgent development of methods to predict histopathological response to neoadjuvant therapies for GEJ adenocarcinoma. Published data demonstrate that clinicopathological features (tumor location), imaging (fluorodeoxyglucose-positron emission tomography "metabolic response"), and tissue/molecular biomarkers may all have a predictive value for neoadjuvant therapies. However, it is uncertain from published data whether or not they will be useful for clinical decision making in individual patients. Existing candidate biomarkers need to be properly qualified and validated and novel biomarkers are required; and an optimal approach should involve the combination and integration of clinical, imaging, and molecular biomarkers. This review presents the evidence base and discusses novel experimental approaches for the combination of biomarker modalities to allow optimization of an individualized treatment approach in GEJ adenocarcinoma patients that may be relevant to other tumor types as well.

    AB - The incidence of adenocarcinomas of the gastroesophageal junction (GEJ) is rapidly rising, and even in early-stage locoregional confined disease the 5-year survival rate rarely exceeds 25%-35%. Randomized trials and meta-analyses have demonstrated a benefit with neoadjuvant or perioperative chemotherapy and with neoadjuvant chemoradiotherapy. However, the optimal approach in individual patients is not clear and remains controversial. A consistent finding is that patients who have a histopathological response to neoadjuvant therapy are more likely to receive a survival benefit. These clinical data provide a strong argument for the urgent development of methods to predict histopathological response to neoadjuvant therapies for GEJ adenocarcinoma. Published data demonstrate that clinicopathological features (tumor location), imaging (fluorodeoxyglucose-positron emission tomography "metabolic response"), and tissue/molecular biomarkers may all have a predictive value for neoadjuvant therapies. However, it is uncertain from published data whether or not they will be useful for clinical decision making in individual patients. Existing candidate biomarkers need to be properly qualified and validated and novel biomarkers are required; and an optimal approach should involve the combination and integration of clinical, imaging, and molecular biomarkers. This review presents the evidence base and discusses novel experimental approaches for the combination of biomarker modalities to allow optimization of an individualized treatment approach in GEJ adenocarcinoma patients that may be relevant to other tumor types as well.

    KW - Adenocarcinoma

    KW - Diagnostic Imaging

    KW - Esophageal Neoplasms

    KW - Esophagogastric Junction

    KW - Humans

    KW - Prognosis

    KW - Stomach Neoplasms

    KW - Treatment Outcome

    KW - Tumor Markers, Biological

    U2 - 10.1634/theoncologist.2009-0293

    DO - 10.1634/theoncologist.2009-0293

    M3 - Article

    VL - 15

    SP - 270

    EP - 284

    JO - Oncologist

    JF - Oncologist

    SN - 1083-7159

    IS - 3

    ER -